CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
Gallarate, VA, Italy and 72 other locations
In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...
Phase 2
Pavia, Italy and 76 other locations
(Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple...
Phase 1
Milan, Lombardy, Italy and 31 other locations
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...
Phase 3
Milan, Lombardy, Italy and 104 other locations
as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering...
Milan, Italy and 5 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Novara, Italy and 243 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Pavia, PV, Italy and 249 other locations
of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple...
Phase 3
Pavia, PV, Italy and 58 other locations
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥1...
Phase 3
Milan, Milano, Italy and 352 other locations
) neo-antigen in subjects with relapsing multiple sclerosis (RMS).COVID-19 sub-study:The purpose of this research sub-study is to e...
Phase 3
Lugano, Switzerland and 298 other locations
Clinical trials
Research sites
Resources
Legal